Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Gefitinib in Previously Treated Advanced NSCLC
ChiCTR-TRC-09000506Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Icotinib arm with Gefitinib arm (2 arms). Primary endpoint: Progression-Free Survival. Started Feb 2009; status: completed.
02
Drugs
icotinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000506.